---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-080501"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2026-07-06T10:00:41+00:00"
generated_at: "2026-07-06T10:05:28.319429+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics enters Tenth Amendment with Oaktree; defers principal, reduces liquidity covenant to $7.5M

## Summary
- Payment of $9,016,914.47 (principal and interest) deferred from June 30 to July 31, 2026.
- Minimum liquidity covenant reduced from $12.5M to $7.5M.
- Company must enter definitive agreements by July 31, 2026 for a transaction to repay all obligations or alternative capital solutions.
- Strategic Process Committee established with David Mack to oversee restructuring, sale, or bankruptcy filing.
- Additional negative covenants, weekly lender meetings, and bi-weekly cash flow budgets imposed.

## SEC filing metadata
- accession: 0001104659-26-080501
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2026-07-06T10:00:41+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465926080501/0001104659-26-080501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465926080501/tm2619779d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-080501
- JSON: https://secwatch.observer/filing/0001104659-26-080501.json
- Plain text: https://secwatch.observer/filing/0001104659-26-080501.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.